[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Adelaide\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":157},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,73,101,126],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100588499","effects-of-calcium-on-gut-functions-and-blood-glucose-in-humans-with-type-2-diabetes-100588499",false,"NCT06942195","Effects of Calcium on Gut Functions and Blood Glucose in Humans With Type 2 Diabetes","Effects of Intraduodenal Calcium on Plasma Glucose, Glucoregulatory Hormones and Gastric Emptying in Response to a Mixed-nutrient Drink in Humans With Type 2 Diabetes","Inclusion Criteria:\n\n* Males with type 2 diabetes mellitus (T2DM). Diagnosis of T2DM will be based on WHO criteria. Only males will be included to avoid the confounding effects of the menstrual cycle on gastric emptying.\n* BMI: 28-38 kg\u002Fm².\n* HbA1c \\>=6.5 - \\\u003C=7.9% at screening.\n* Blood glucose medications will be required to be withheld for 48 hours prior to each study day.\n* Weight-stable (i.e. \\\u003C5% fluctuation) at study entry, which will be ascertained by a stable body weight in the preceding 3 months.\n\nExclusion Criteria:\n\n* Significant GI symptoms, or history of GI disease or surgery\n* Current gallbladder or pancreatic disease\n* Cardiovascular or respiratory diseases\n* Any other illnesses (except type 2 diabetes) as assessed by the investigator - (including chronic illnesses not explicitly listed above)\n* Use of prescribed or non-prescribed medications (including vitamins and herbal supplements) which may affect energy metabolism, GI function, bodyweight or appetite (e.g. domperidone, cisapride, anticholinergic drugs (e.g. atropine), metoclopramide, erythromycin, hyoscine, orlistat, green tea extracts, Astragalus, St Johns Wort etc.)\n* Lactose intolerance\u002Fother food allergy(ies)\n* Individuals with low ferritin levels (\\\u003C30 ng\u002FmL), or who have donated blood in the 12 weeks prior to taking part in the study\n* High performance athletes\n* Current intake of \\> 2 standard drinks on \\> 5 days per week (\\>140g\u002Fweek)\n* Current smokers of tobacco (cigarettes, cigars, pipes, sheesha, chewing, vaping etc.)\n* Current use of recreational drugs, e.g. marijuana\n* Current intake of any illicit substance\n* Vegetarians\n* Inability to tolerate nasoduodenal tube\n* Inability to comprehend study protocol\n* HbA1c \\\u003C6% or \\>7.9%\n* Estimated glomerular filtration rate \\\u003C45 ml\u002Fmin\n* Any patient whose medication cannot be withheld for 48 hours for medical reasons","MALE","18 Years","70 Years",{"count":20,"type":21},8,"ESTIMATED","INTERVENTIONAL",[24],"NA","The intervention in this study consists of a 75-min intraduodenal infusion of an isotonic solution containing either of calcium chloride (CaCl2) or control (saline).\n\nParticipants enrolled into the study will receive, in randomised, double-blind fashion (i) Saline (control), (ii) 500 mg CaCl2, or (iii) 1000 mg CaCl2 in three separate sessions, each of which will be separated by at least 4 (and up to 10) days. Each study session will be 4-6 hours. Studies will be carried out in the Clinical Research Facility of the Adelaide Medical School, the University of Adelaide, by staff and students trained in the required techniques.",[27],"T2DM",[29,30,31,32,33,34],"Intraduodenal","Calcium","Gastric emptying","Glucoregulatory hormones","Plasma glucose","Human","RECRUITING","2025-12-18",{"date":38,"type":39},"2025-12-26","ACTUAL",{"date":41,"type":39},"2025-05-22",{"date":43,"type":21},"2026-04-28",{"name":45,"class":46},"University of Adelaide","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":47},"100593993","effects-of-combined-administration-of-calcium-and-l-tryptophan-on-gut-functions-and-blood-glucose-in-healthy-humans-100593993","NCT07013656","Effects of Combined Administration of Calcium and L-tryptophan on Gut Functions and Blood Glucose in Healthy Humans","Effects of Combined Intraduodenal Administration of Calcium and L-tryptophan on Plasma Glucose, Glucoregulatory Hormones and Gastric Emptying in Response to a Mixed-nutrient Drink in Healthy Adult Males","Inclusion Criteria:\n\n* Healthy, lean males (only men will be included in the study to avoid the confounding effects of the menstrual cycle on gastric emptying).\n* BMI: 19-25 kg\u002Fm2,\n* Weight-stable (i.e. \\\u003C5% fluctuation) at study entry, which will be ascertained by a stable body weight in the preceding 3 months.\n\nExclusion Criteria:\n\n* Significant GI symptoms, or history of GI disease or surgery\n* Current gallbladder or pancreatic disease\n* Cardiovascular or respiratory diseases\n* Any other illnesses as assessed by the investigator (including chronic illnesses not explicitly listed above)\n* Use of prescribed or non-prescribed medications (including vitamins and herbal supplements) which may affect energy metabolism, GI function, body weight or appetite (e.g. domperidone, cisapride, anticholinergic drugs (e.g. atropine), metoclopramide, erythromycin, hyoscine, orlistat, green tea extracts, Astragalus, St Johns Wort etc.)\n* Lactose intolerance\u002Fother food allergy(ies)\n* Individuals with low ferritin levels (\\\u003C30 ng\u002FmL), or who have donated blood in the 12 weeks prior to taking part in the study\n* High performance athletes\n* Current intake of \\> 2 standard drinks on \\> 5 days per week (\\>140g\u002Fweek)\n* Current smokers of tobacco (cigarettes, cigars, pipes, sheesha, chewing, vaping etc.)\n* Current use of recreational drugs, e.g. marijuana\n* Current intake of any illicit substance\n* Vegetarians\n* Inability to tolerate nasoduodenal tube\n* Inability to comprehend study protocol\n* Restrained eaters (score \\>12 on the 3-factor eating questionnaire)",true,{"count":57,"type":21},16,[24],"The intervention in this study consists of 75-minute intraduodenal infusions of isosmotic solutions containing either saline (control), L-tryptophan, or calcium combined with L-tryptophan. Participants enrolled into the study will receive, in a randomised, double-blind fashion either (i) saline (control), (ii) L-tryptophan at a rate of 0.1 kcal\u002Fminute, (iii) combination of L-tryptophan (0.1 kcal\u002Fminute) + 500 mg calcium, or (iv) combination of L-tryptophan (0.1 kcal\u002Fminute) + 1000 mg calcium in four separate sessions, each of which will be separated by at least 4 (and up to 10) days. Each study session will be 4-6 hours. Studies will be carried out in the Clinical Research Facility of the Adelaide Medical School, the University of Adelaide, by staff and students trained in the required techniques.",[61],"Healthy",[29,30,63,31,32,33,34],"L-tryptophan","NOT_YET_RECRUITING","2025-06-18",{"date":67,"type":39},"2025-06-24",{"date":69,"type":21},"2025-06-28",{"date":71,"type":21},"2026-11-25",{"name":45,"class":46},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":80,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":47},"100584527","phase-2-the-anti-anginal-effects-of-n-acetylcysteine-nac-in-patients-with-angina-and-non-obstructive-coronary-arteries-anoca-100584527","NCT06890507","The Anti-Anginal Effects of N-Acetylcysteine (NAC) in Patients with Angina and Non-Obstructive Coronary Arteries (ANOCA)","NANA","Inclusion Criteria:\n\n1. Provision of informed consent prior to any study specific procedures\n2. Female patients aged ≥18 years\n3. No obstructive CAD (defined as either absence of epicardial lesions with ≥50% luminal narrowing in any coronary artery segment on coronary angiography or normal findings on computed tomography (CT) angiogram, indicating the absence of significant stenosis) to account for chest pain symptoms.\n4. Chest pain occurring ≥3 times\u002Fweek in the preceding two weeks.\n\nExclusion Criteria:\n\n1. Known allergy to NAC or its components.\n2. Acute myocardial infarction admission within the preceding month (hospital admission for prolonged angina paint associated with a cardiac troponin level above the 99th percentile, with a subsequent rise or fall).\n3. Secondary causes of angina including:\n\ni. clinically significant anaemia (haemoglobin \\\u003C100g\u002FdL) ii. uncontrolled atrial fibrillation (ventricular response rate \\>108bpm) iii. haemodynamically significant aortic stenosis (mean valve gradient ≥40mmHg) d) Known concomitant disease with life expectance of less than 1 year. e) Abnormalities in liver function tests suggesting hepatic impairment (ALT and\u002For AST 2 x upper limit of normal (ULN) or ALP 2 x ULN or Bilirubin 1.5 x ULN) f) Severe renal impairment (eGFR \\\u003C30mL\u002Fmin) or on dialysis. g) Pregnancy or lactation. h) Untreated hypertension i) Unwilling, or unable, to give informed consent, including due to severe psychiatric conditions affecting informed consent process or compliance.\n\nj) History of substance abuse. k) Currently taking Chloroquine. l) Serious or unstable medical conditions that may interfere with the study, as determined by the PI.\n\nm) Concomitant participation in another clinical trial or research study (except where in the opinion of the PI, the participant could benefit from enrolling in another trial)","FEMALE",{"count":82,"type":21},25,[84],"PHASE2","The goal of this clinical trial is to determine if N-acetylcysteine (NAC) can reduce angina frequency in women with Angina with Non-Obstructive Coronary Arteries (ANOCA). It will also assess the impact of NAC on health status and quality of life. The main questions it aims to answer are:\n\n(i) Does NAC reduce the number of angina episodes per week? (ii) How does NAC affect quality of life and symptom burden in ANOCA patients? (iii) Does NAC reduce the need for short-acting nitrate use?\n\nResearchers will compare NAC to a placebo in a randomized, double-blind, placebo-controlled crossover study to determine its effectiveness.\n\nParticipants will receive treatment with NAC 600mg twice daily for 4 weeks (28 days) and matched placebo for 4 weeks (28 days) in a computer-generated random order giving a total dosing period of 8 weeks. There will be a 2-week washout between the two treatment periods.\n\nThe effectiveness of N-Acetylcysteine (NAC) will be assessed using the following measures:\n\nAngina Diary: Participants will record the frequency and severity of their angina episodes.\n\nSeattle Angina Questionnaire-7 (SAQ-7): Participants will complete this questionnaire to assess physical limitations, angina frequency, and quality of life.\n\nEuroQol 5-Dimension (EQ-5D) Questionnaire: Participants will rate their overall health and quality of life.",[87,88],"Angina Attacks","Non Obstructive Coronary Artery Disease",[90,91,92],"ANOCA","Angina with Non Obstructive Coronary Arteries","N-acetylcysteine","2025-03-16",{"date":95,"type":39},"2025-03-24",{"date":97,"type":21},"2025-06-01",{"date":99,"type":21},"2027-09-01",{"name":45,"class":46},{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":55,"sex":80,"minAge":109,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":47},"100429209","effects-of-an-evening-protein-preload-on-metabolic-health-in-night-shift-workers-propensity-100429209","NCT04869098","Effects of an Evening PROtein PrEload on Metabolic Health in Night ShIfT Workers (PROPENSITy)","Effects of an Evening PROtein PrEload on Blood Glucose, Metabolic Health, and Gut Hormone Release in Night ShIfT Workers (PROPENSITy)","PROPENSITy","Inclusion Criteria:\n\n* Female\n* Night shift workers (with a minimum of 6 months in their current shift work schedule)\n* 35-65 years\n* BMI 28.0-35.0 kg\u002Fm2; waist circumference \\> 80cm\n* Weight stable in the past 6 months\n\nExclusion Criteria:\n\n* Those working standard day time hours only, or those who work less than three to four night shifts per fortnight on average\n* Personal history and\u002For diagnosis of: diabetes, cancer, major psychiatric disorders, liver disease, gastro-intestinal surgery or disease (including malabsorption), eating disorders, anaemia, insomnia or cardiovascular disease, and\u002For any other condition deemed unstable by the study physician\n* Taking medications known to alter body composition or metabolism, including (but not limited to): any medication used to lower blood glucose or antidiabetic medications (metformin, sulfonylureas, Glucagon-like peptide-1 (GLP-1) analogues \\[i.e. exenatide\\], thiazolidinediones or DPP-IV inhibitors \\[i.e. 'gliptins'\\]), medications affecting weight, appetite or gut motility (i.e. diuretics, domperidone, cisapride, orlistat, phentermine, topiramate)\n* Participants who are taking stable doses (i.e. \\> 12 months) of androgenic medications (i.e. testosterone) or SSRI's will not be excluded. Personal history\u002Fdiagnosis (self-reported) of diabetes (type 1 or 2), major psychiatric disorders (schizophrenia, major depressive disorder, bipolar disorder, eating disorders), gastrointestinal disorders, haematological disorders (i.e. thalassemia, iron-deficiency anaemia) insomnia, or any other medical condition, deemed unstable by the study physician\n* Pregnant, planning a pregnancy or breastfeeding\n* Those who have lost or gained \\>5% of body weight in the last 6 months\n* Those who consume four or more standard drinks on a single occasion at a 'daily or almost daily' occurrence\n* current smokers of cigarettes\u002Fmarijuana\u002Fe-cigarettes\u002Fvaporisers\n* unable to comprehend the study protocol (i.e. due to English language or cognitive difficulties)","35 Years","65 Years",{"count":112,"type":21},30,[24],"This study will compare the effects of a whey protein supplement or a placebo consumed before the evening meal on health outcomes in night shift workers.",[116,117],"Type 2 Diabetes","Shift-work Disorder","2024-12-18",{"date":120,"type":39},"2024-12-24",{"date":122,"type":39},"2021-04-27",{"date":124,"type":21},"2026-07-31",{"name":45,"class":46},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":133,"minAge":17,"maxAge":4,"enrollmentInfo":134,"targetDuration":136,"studyType":137,"phases":4,"briefSummary":138,"conditions":139,"keywords":142,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":47},"100503517","the-arrc-iii-trial-of-advanced-recovery-room-care-arrc-100503517","NCT05836285","The ARRC III Trial of Advanced Recovery Room Care (ARRC).","ARRCIII","Inclusion Criteria:\n\n* Scheduled for elective or unplanned surgery\n* Scheduled to stay in hospital at least one night after surgery\n* 30-day mortality of 0.5% to 8% by the US National Safety and Quality Improvement Program risk score (NSQIP)\n\nExclusion Criteria:\n\n* Undergoing cardiac surgery\n* Scheduled for postoperative Intensive Care Unit management","ALL",{"count":135,"type":21},3000,"18 Months","OBSERVATIONAL","A postoperative high-acuity model of care (ARRC) has been shown, in a prospective cohort study of approximately 850 patients, to produce a marked improvement in patient and hospital outcomes, and hospital costs, in medium risk patients (Ludbrook G et al., JAMA Surgery 2023).\n\nThe goal of this observational study is to examine the outcomes after non-cardiac surgery of a larger group of medium risk patients receiving different forms of care -ARRC and usual ward care. The main questions it aims to answer are:\n\nwhat are the outcomes for patients and hospital after the different forms of care, who receives benefit from high acuity care, what underlies the improved outcomes seen with high acuity care.",[140,141],"Post-Surgical Complication","Economic Problems",[143,144,145,146,147,148],"postoperative complications","safety","health economics","quality of recovery after surgery","surgery","anaesthesia","2024-08-11",{"date":151,"type":39},"2024-08-14",{"date":153,"type":39},"2023-04-18",{"date":155,"type":21},"2025-12",{"name":45,"class":46},""]